Hematology

CAR-T

Questions discussed in this category

What criteria is needed in relapsed/refractory B-cell ALL to choose CAR-T therapy over conventional stem cell transplant as destination therapy?

1 Answer available

What is your approach to pediatric or AYA patients with B-cell ALL who relapse after CD-19 CAR-T?

1 Answer available

What is your treatment of choice for triple class refractory multiple myeloma?

CAR-T (any specific preference of product?) vs bispecific antibodies vs any other specific agents not previously utilized?

2 Answers available

How do you incorporate CAR-T cell therapy in the second-line setting for DLBCL in transplant-eligible patients?

How do you assess chemosensitive vs chemorefractory disease? Given the results of ZUMA-7, TRANSFORM, and BELINDA - will you be altering your current ...

4 Answers available

Papers discussed in this category

J Clin Oncol, 2021 Dec 9

Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.

Blood Cancer Discov, 2021 Dec 01

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia.

Hematology

CAR-T

Questions discussed in this category

Papers discussed in this category

Related Topics in Hematology